High glucose levels abolish antiatherosclerotic benefits of ACE inhibition in alloxan-induced diabetes in rabbits

High glucose levels abolish antiatherosclerotic benefits of ACE inhibition in alloxan-induced diabetes in rabbits

Author Pomaro, D. R. Google Scholar
Ihara, SSM Google Scholar
Pinto, Leonor do Espírito Santo de Almeida Autor UNIFESP Google Scholar
Ueda, Ivete Autor UNIFESP Google Scholar
Casarini, Dulce E. Autor UNIFESP Google Scholar
Ebihara, Fabiana Autor UNIFESP Google Scholar
Santos, Andreza O. Autor UNIFESP Google Scholar
Izar, Maria Cristina de Oliveira Autor UNIFESP Google Scholar
Fonseca, Francisco Antonio Helfenstein Autor UNIFESP Google Scholar
Institution Universidade Federal de São Paulo (UNIFESP)
Abstract Renin-angiotensin system activation is recognized to play an important role in atherosclerosis. This study aimed to verify the antiatherosclerotic effects of ACE inhibition on an experimental model of diabetes and hypercholesterolemia. Diabetes was induced in New Zealand male rabbits with a single dose of alloxan (100 mg/kg, IV), and, according to plasma glucose levels obtained after 1 week, the animals were divided into 2 groups (>= 250 mg/dL or < 250 mg/dL). Each group was randomly assigned to receive or not quinapril (30 mg/d) added to a 0.5% cholesterol-enriched diet. Animals with high glucose levels at 1 week and that remained high after 12 weeks presented higher triglyceride levels (P < 0.02 versus basal). Those initially hyperglycemic but presenting < 250 mg/dL glucose at the end of study formed an additional group. Plasma ACE activity was lower in quinapril-treated animals (P < 0.01 versus untreated groups). However, aorta intima/media ratio and intima area were lower only in the subgroups of quinapril-treated animals with low glucose levels (P < 0.05). Our results support the hypothesis that high plasma glucose may abolish the anti atheroscl erotic effect of ACE inhibitors.
Keywords ACE inhibitor
atherosclerosis
diabetes
cholesterol
rabbits
Language English
Date 2005-04-01
Published in Journal of Cardiovascular Pharmacology. Philadelphia: Lippincott Williams & Wilkins, v. 45, n. 4, p. 295-300, 2005.
ISSN 0160-2446 (Sherpa/Romeo, impact factor)
Publisher Lippincott Williams & Wilkins
Extent 295-300
Origin http://dx.doi.org/10.1097/01.fjc.0000155384.64350.45
Access rights Open access Open Access
Type Article
Web of Science ID WOS:000227939100004
URI http://repositorio.unifesp.br/handle/11600/28200

Show full item record




File

File Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)

Search


Browse

Statistics

My Account